Bal Pharma
BALPHARMA NSE
Bal Pharma
HealthcareNSE: BALPHARMA BSE: 524824 Pharmaceuticals
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹176 Cr
Volatility
Moderate
P/E Ratio
23.77
EBITDA
₹31.90 Cr
Return on Equity
9.35%
Debt to Equity
1.95
Book Value
₹51.65
52W High
₹124.6
52W Low
₹60
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
1- Company has been maintaining a healthy dividend payout of 27.5%
Weaknesses
4- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 4.46% over past five years.
- Tax rate seems low
- Company has a low return on equity of 9.37% over last 3 years.
Growth Rate
Revenue Growth
2.08% higher than
3Y
Net Income Growth
-17.64% lower than
3Y
Cash Flow Change
-10.92%
ROE
-9.66% lower than
3Y
ROCE
-6.05% lower than
3Y
EBITDA Margin (Avg.)
-2.21% lower than
3Y
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 70.39 | 92.54 | 81.66 | 94.63 | 74.36 | 73.69 | 73.15 | 81.88 | 65.87 | 74.02 | 87.69 | 84.08 | 88.62 |
| Expenses | 63.95 | 84.84 | 73.87 | 85.03 | 67.89 | 66 | 65.4 | 74.24 | 59.81 | 68.29 | 78.15 | 73.5 | 80.67 |
| Operating Profit | 6.44 | 7.7 | 7.79 | 9.6 | 6.47 | 7.69 | 7.75 | 7.64 | 6.06 | 5.73 | 9.54 | 10.58 | 7.95 |
| OPM % | 9.15% | 8.32% | 9.54% | 10.14% | 8.7% | 10.44% | 10.59% | 9.33% | 9.2% | 7.74% | 10.88% | 12.58% | 8.97% |
| Other Income | 0.16 | 0.14 | 0.1 | 2.45 | 0.82 | -0.2 | 0.51 | 1.08 | 0.72 | 1.12 | 0.33 | -0.24 | 0.44 |
| Interest | 3.64 | 3.82 | 3.66 | 4.14 | 4.24 | 3.65 | 5.01 | 3.95 | 4.05 | 3.86 | 4.85 | 4.06 | 4.47 |
| Depreciation | 2.53 | 2.42 | 2.96 | 2.16 | 2.43 | 2.48 | 2.69 | 2.18 | 2.52 | 2.27 | 3.23 | 3.06 | 2.78 |
| PBT | 0.43 | 1.6 | 1.27 | 5.75 | 0.62 | 1.36 | 0.56 | 2.59 | 0.21 | 0.72 | 1.79 | 3.22 | 1.14 |
| Tax % | 79.07% | 39.38% | 33.07% | 3.65% | 58.06% | 23.53% | 7.14% | -108.88% | 0% | 0% | 0% | -12.11% | 0% |
| Net Profit | 0.09 | 0.97 | 0.85 | 5.53 | 0.26 | 1.04 | 0.52 | 5.41 | 0.21 | 0.72 | 1.79 | 3.6 | 1.13 |
| EPS in Rs | 0.05 | 0.61 | 0.56 | 3.46 | 0.16 | 0.65 | 0.3 | 3.41 | 0.13 | 0.45 | 1.12 | 2.25 | 0.7 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 187 | 198 | 229 | 211 | 225 | 171 | 251 | 281 | 304 | 339 | 303 | 312 | 334 |
| Expenses | 170 | 183 | 214 | 194 | 207 | 166 | 226 | 257 | 279 | 308 | 273 | 280 | 301 |
| Operating Profit | 17 | 15 | 15 | 17 | 18 | 5 | 25 | 24 | 25 | 31 | 30 | 32 | 34 |
| OPM % | 9% | 7% | 6% | 8% | 8% | 2.9% | 10% | 9% | 8% | 9% | 10% | 10% | 10% |
| Other Income | 1 | 1 | 3 | 2 | 1 | 2 | 1 | 5 | 1 | 3 | 2 | 2 | 2 |
| Interest | 7 | 6 | 8 | 9 | 13 | 13 | 12 | 11 | 12 | 15 | 17 | 17 | 17 |
| Depreciation | 7 | 7 | 6 | 7 | 6 | 8 | 10 | 9 | 9 | 10 | 10 | 11 | 11 |
| PBT | 5 | 3 | 3 | 3 | 0 | -14 | 4 | 9 | 5 | 9 | 5 | 6 | 7 |
| Tax % | 25% | 90% | 114% | 87% | -1175% | -5% | -15% | 38% | 45% | 18% | -41% | -7% | — |
| Net Profit | 4 | 1 | 0 | 0 | 2 | -13 | 5 | 6 | 3 | 7 | 7 | 6 | 7 |
| EPS in Rs | 2.82 | 1.1 | 1.24 | 1.96 | 2.67 | -8.62 | 3.2 | 3.78 | 1.64 | 4.68 | 4.53 | 3.94 | 4.52 |
| Div. Payout % | 35% | 91% | 81% | 51% | 37% | 0% | 31% | 26% | 61% | 26% | 26% | 30% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13 | 13 | 14 | 14 | 14 | 14 | 15 | 15 | 16 | 16 | 16 | 16 |
| Reserves | 42 | 42 | 48 | 51 | 52 | 38 | 39 | 44 | 48 | 56 | 62 | 66 |
| Borrowings | 49 | 89 | 93 | 110 | 124 | 118 | 110 | 104 | 131 | 140 | 150 | 160 |
| Other Liabilities | 59 | 67 | 78 | 86 | 71 | 68 | 76 | 98 | 116 | 108 | 108 | 134 |
| Total Liabilities | 164 | 211 | 233 | 260 | 261 | 238 | 240 | 261 | 311 | 320 | 336 | 376 |
| Fixed Assets | 52 | 56 | 60 | 71 | 70 | 71 | 69 | 67 | 76 | 80 | 87 | 94 |
| CWIP | 1 | 4 | 2 | 0 | 4 | 3 | 0 | 2 | 0 | 0 | 3 | 7 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 2 | 2 |
| Other Assets | 111 | 151 | 172 | 188 | 187 | 164 | 172 | 192 | 235 | 233 | 244 | 272 |
| Total Assets | 164 | 211 | 233 | 260 | 261 | 238 | 240 | 261 | 311 | 320 | 336 | 376 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 15 | -19 | 6 | 1 | 8 | 23 | 22 | 27 | -2 | 23 | 20 | 30 |
| Investing | -5 | -14 | -8 | -4 | -8 | -5 | -6 | -9 | -22 | -19 | -15 | -21 |
| Financing | -7 | 32 | -6 | 4 | 0 | -20 | -17 | -17 | 24 | -1 | -8 | -10 |
| Net Cash Flow | 2 | -1 | -8 | 1 | 0 | -2 | 0 | 0 | 0 | 3 | -2 | 0 |
| Free Cash Flow | 9 | -34 | -2 | -3 | -1 | 18 | 19 | 18 | -16 | 12 | 2 | 8 |
| CFO/OP | 93 | -125 | 52 | 11 | 57 | 465 | 91 | 117 | -4 | 88 | 75 | 95 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 88 | 105 | 99 | 111 | 105 | 106 | 98 | 98 | 113 | 107 | 111 | 110 |
| Inventory Days | 132 | 145 | 172 | 240 | 217 | 292 | 146 | 162 | 207 | 167 | 238 | 269 |
| Days Payable | 142 | 163 | 171 | 182 | 147 | 167 | 114 | 143 | 167 | 147 | 189 | 206 |
| Cash Conversion Cycle | 78 | 87 | 100 | 168 | 175 | 231 | 130 | 117 | 153 | 127 | 161 | 173 |
| Working Capital Days | 14 | 50 | 26 | 45 | 25 | -11 | 11 | 18 | 13 | 12 | 6 | 7 |
| ROCE % | 11% | 7% | 8% | 8% | 7% | 0% | 10% | 12% | 10% | 12% | 10% | 10% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Bal Pharma insights
63 extracted metrics + investor summaries across FY11–FY26.
Documents
1
Clarification sought from Bal Pharma Ltd
10 Sep - Exchange has sought clarification from Bal Pharma Ltd on September 10, 2026 with reference to significant movement in price, in order to ensure that investors … 10 Sep - Exchange has sought clarification from Bal Pharma Ltd on September 10, 2026 with reference to significant movement in price, in order to ensure that investors …
2
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
6 Apr - Confirmed Regulation 74(5) compliance for demat/remat details for quarter ended 31 March 2026. 6 Apr - Confirmed Regulation 74(5) compliance for demat/remat details for quarter ended 31 March 2026.
4
Announcement under Regulation 30 (LODR)-Change in Management
1 Mar - Prasun Banerjee resigned as Company Secretary, Compliance Officer and KMP effective March 1, 2026. 1 Mar - Prasun Banerjee resigned as Company Secretary, Compliance Officer and KMP effective March 1, 2026.
5
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
1 Mar - Company Secretary and Compliance Officer Prasun Banerjee resigned effective March 1, 2026. 1 Mar - Company Secretary and Compliance Officer Prasun Banerjee resigned effective March 1, 2026.
Frequently Asked Questions about Bal Pharma
What does Bal Pharma Ltd do?
Incorporated in 1987, Bal Pharma Ltd does manufacturing and selling of pharmaceutical products and related services[1]
Where is Bal Pharma Ltd (BALPHARMA) listed?
Bal Pharma Ltd trades as BALPHARMA on the NSE and under code 524824 on the BSE.
Which sector does Bal Pharma Ltd belong to?
Bal Pharma Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Bal Pharma Ltd?
Bal Pharma Ltd has a market capitalisation of ₹175.62 Cr, which places it in the Small Cap band.
What is the PE ratio of Bal Pharma Ltd?
Bal Pharma Ltd trades at a PE ratio of 23.77, against a book value of ₹51.65 per share.
What is the 52-week high and low of Bal Pharma Ltd?
Over the last 52 weeks Bal Pharma Ltd has traded between ₹60 and ₹124.6.
Does Bal Pharma Ltd pay dividends?
Bal Pharma Ltd has a dividend yield of 1.13%.
What is the Return on Equity (ROE) of Bal Pharma Ltd?
Bal Pharma Ltd reported a return on equity of 9.35%. Its debt-to-equity ratio is 1.95.
Company Information
Incorporated in 1987, Bal Pharma Ltd does manufacturing and selling of pharmaceutical products and related services[1]
Website balpharma.com
CEO Mr. Shailesh Dheerajmal Siroya
Employees 986
Listed 2006-05-08
Face Value ₹ 10
Issued Size 1,59,20,872
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/BALPHARMA.md for Bal Pharma Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.